- The S2 Hurdle: How the current funding pathway is restricting cross-border access for rare disease treatments
- What is the role of commercial arrangements in ensuring patients have timely access to new medicines?
- Cochrane’s collaborative agreement with NICE
- Big Pharma double-digit price hikes
News